Page results
-
This patient information is intended to help patients suffering from long COVID to better manage and understand their fatigue.
-
This leaflet has written by the administration team at the National Hospital for Neurology and Neurosurgery for outpatients.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
An immunotherapy drug given before surgery instead of chemotherapy meant that significantly more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
This patient information provides possible explanations for the causes of long COVID.
-
What to expect from your neuro-oncology Clinical Nurse Specialist (key worker) at the NHNN
-
The Sickle Cell Society (SCS) and the UK Thalassaemia Society (UKTS) have worked in partnership with the NHS sickle cell and thalassaemia (SCT) screening programme to engage with communities less likely to access health information through usual NHS channels. The societies provide feedback from people that share the same population background or have experience of the condition and to feed into the programme updates and improvements.
-
Information about the Integrated Cancer Care Service for children and young adults at the RLHIM.
-
Information about the Integrated Children and Adolescent Service at the RLHIM
File results
-
FOI/2022/0437 - IT infrastructure systems used at Trust
-
FOI/2022/0443 - Trust spend on lost, stolen or damaged patient property
-
FOI/2022/0448 - Electronic cloud based job evaluation system
-
FOI/2022/0449 - Use of defibrotide for the treatment of Hepatic Veno-occlusive disease
-
FOI/2022/0451 - Patient information leaflets
-
FOI/2022/0454 - Temporary staff waiting list initiative and overtime spend
-
FOI/2022/0456 - Treatment of renal cell carcinoma
-
FOI/2022/0459 - Interpreters and translation services
-
FOI/2022/0465 - Treatment of dermatological conditions
-
FOI/2022/0466 - Rare diseases diagnosis and treatment